JoinClinicalTrials.com

• A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

  NCT03538041

  Condition:   Autoimmune Hemolytic Anemia
  Intervention:   Drug: Parsaclisib
  Sponsor:   Incyte Corporation
  Recruiting
• A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

  NCT04138927

  Condition:   Warm Antibody Autoimmune Hemolytic Anemia
  Intervention:   Drug: Fostamatinib disodium
  Sponsor:   Rigel Pharmaceuticals
  Not yet recruiting
• Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

  NCT04119050

  Condition:   Warm Autoimmune Hemolytic Anemia
  Interventions:   Drug: M281;   Drug: Placebo
  Sponsor:   Momenta Pharmaceuticals, Inc.
  Recruiting
• Data Registry of Auto Immune Hemolytic Anemia

  NCT04024202

  Condition:   Autoimmune Hemolytic Anemia
  Intervention:  
  Sponsors:   Sanquin Research & Blood Bank Divisions;   Leiden University Medical Center;   Radboud University;   UMC Utrecht;   Maastricht University Medical Center;   Erasmus Medical Center;   Haga Hospital;   Isala;   Jeroen Bosch Ziekenhuis;   St. Antonius Hospital;   Onze Lieve Vrouwe Gasthuis;   Spaarne Gasthuis;   Amsterdam University Medical Center;   Sanquin Plasma Products BV
  Recruiting
• Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

  NCT04083014

  Conditions:   Autoimmune Hemolytic Anemia;   Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
  Intervention:   Drug: combination of a single dose anti-CD20 antibody and bortezomib
  Sponsor:   Peking Union Medical College Hospital
  Recruiting
• Immunopathology of Autoimmune Hemolytic Anemia

  NCT02158195

  Condition:   Autoimmune Hemolytic Anemia
  Intervention:   Biological: blood samples
  Sponsor:   Centre Hospitalier Universitaire Dijon
  Recruiting
• Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)

  NCT02828670

  Condition:   Autoimmune Hemolytic Anemia
  Interventions:   Biological: blood sample;   Procedure: spleen sample
  Sponsor:   Centre Hospitalier Universitaire Dijon
  Recruiting
• Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia

  NCT03827603

  Condition:   AIHA - Warm Autoimmune Hemolytic Anemia
  Intervention:   Drug: Ibrutinib
  Sponsor:   Eugene Nikitin
  Recruiting
• A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

  NCT03764618

  Condition:   Warm Antibody Autoimmune Hemolytic Anemia
  Interventions:   Drug: Fostamatinib disodium;   Drug: Placebo
  Sponsor:   Rigel Pharmaceuticals
  Recruiting
• A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA ITP

  NCT04039477

  Conditions:   Autoimmune Hemolytic Anemia;   Immune Thrombocytopenia
  Intervention:   Drug: KZR-616
  Sponsor:   Kezar Life Sciences, Inc.
  Recruiting
• Autoimmune Cytopenias : Midi-Pyrenees Registry

  NCT02877706

  Conditions:   Immune Thrombocytopenia;   Autoimmune Hemolytic Anemia
  Intervention:   Other: no specific intervention
  Sponsor:   University Hospital, Toulouse
  Recruiting
• Tacrolimus Treatment for Refractory Autoimmune Cytopenia

  NCT03918265

  Conditions:   Autoimmune Hemolytic Anemia;   Pure Red Cell Aplasia;   Evans Syndrome
  Intervention:   Drug: Tacrolimus
  Sponsor:   Peking Union Medical College Hospital
  Recruiting
• Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia

  NCT04005638

  Conditions:   Immune Thrombocytopenia;   Autoimmune Hemolytic Anemia;   Autoimmune Neutropenia
  Interventions:   Biological: blood sample;   Biological: urine sample
  Sponsors:   University Hospital, Bordeaux;   Ministry for Health and Solidarity, France
  Recruiting
• Severe Immune Cytopenia Registry Www.Sic-reg.Org

  NCT03576742

  Conditions:   Immune Thrombocytopenia;   Autoimmune Hemolytic Anemia;   Evan Syndrome;   Primary Immunodeficiency
  Intervention:   Diagnostic Test: potential biomarkers
  Sponsor:   Medical University of Graz
  Recruiting
• Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders

  NCT02502903

  Conditions:   Bullous Pemphigoid (BP);   Cold Agglutinin Disease (CAD);   Warm Autoimmune Hemolytic Anemia (WAIHA);   End-stage Renal Disease (ESRD)
  Interventions:   Drug: BIV009;   Other: Placebo
  Sponsors:   Bioverativ Therapeutics Inc.;   Celerion Clinical Research GmbH;   Assign Data Management and Biostatistics GmbH;   ABF Pharmaceutical Services GmbH;   Quest Diagnostics;   Covance Laboratories - Chantilly
  Recruiting